+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Interferon alpha2a induction therapy in combination with ribavirin and amantadine in naive patients with chronic HCV infection



Interferon alpha2a induction therapy in combination with ribavirin and amantadine in naive patients with chronic HCV infection



Gastroenterology 120(5 Suppl. 1): A 409




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 035159472

Download citation: RISBibTeXText

DOI: 10.1016/s0168-8278(01)81524-5


Related references

Interferon alfa2a induction therapy in combination with ribavirin and amantadine in naive patients with chronic HCV infection. Hepatology 36(4 Part 2): 583A, 2002

Interferon alfa2a induction therapy in combination with ribavirin and amantadine for the treatment of naive patients with chronic HCV infection. Journal of Viral Hepatitis 11(1): 60-68, 2004

Triple therapy with daily induction Interferon-alpha2a , Ribavirin and Amantadine for patients with chronic hepatitis C , who failed to respond to a previous combination treatment protocol Single arm open label pilot study Initial response, safety and tolerability. Hepatology 32(4 Pt 2): 559A, 2000

Treatment of chronic hepatitis C in naive patients with high-dose interferon-alpha2a induction therapy and two different ribavirin doses. Digestive and Liver Disease 36(5): 367-368, 2004

Combination therapy in naive patients with chronic hepatitis C related to genotype 1 Comparison between IFN+Ribavirin and IFN+Amantadine and between Amantadine and Ribavirin addition after 3 months in still viremic patients. Hepatology 36(4 Part 2): 573A, 2002

A randomized controlled trial of amantadine plus interferon-alpha2a vs. interferon-alpha2a alone in naive patients with chronic hepatitis C randomized according to the early virological response to interferon-alpha2a monotherapy. Alimentary Pharmacology & Therapeutics 19(3): 339-347, 2004

Comparison between IFNalpha2a+Ribavirin and IFNalpha2a+Amantadine combination therapy in naive patients with chronic hepatitis C-genotype 1, and between Amantadine and Ribavirin addition in non responders after 3 months. Journal of Hepatology 36(Suppl. 1): 98, 2002

Pegylated or recombinant interferon alfa 2a 3MU TIW in combination with Ribavirin and amantadine versus standard therapy in naive patients with Chronic HCV A randomised controlled trial. Gastroenterology 122(4 Suppl 1): A-306, 2002

A randomised controlled trial on pegylated or recombinant 3MU TIW interferon alpha-2a in combination with Ribavirin and amantadine versus standard therapy in naive patients with chronic HCV. Hepatology 36(4 Part 2): 594A, 2002

The role of triple therapy with amantadine sulphate plus ribavirin and interferon alpha2a on chronic hepatitis c patients. Digestive Disease Week Abstracts & Itinerary Planner : Abstract No T1258, 2003

A randomized trial of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin. Alimentary Pharmacology and Therapeutics 24(7): 1079-1086, 2006

Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine. Wiener Klinische Wochenschrift 116(15-16): 530-535, 2004

Treatment with amantadine + ribavirin + interferon in patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy. Gastroenterology 118(4 Suppl 2 Part 2): AASLD A143, 2000

A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of nonresponder patients with chronic hepatitis C. Journal of Gastroenterology 42(5): 362-367, 2007

Pilot study of interferon-alpha high-dose induction therapy in combination with ribavirin plus amantadine for nonresponder patients with chronic hepatitis C. Zeitschrift für Gastroenterologie 39(2): 145-151, 2001